<DOC>
	<DOCNO>NCT00770172</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor , G-CSF , may increase number white blood cell find bone marrow peripheral blood may prevent persistent neutropenia patient receive chemotherapy . It yet know regimen G-CSF may effective prevent neutropenia . PURPOSE : This randomized phase III trial compare two different regimen G-CSF see well work prevent persistent neutropenia patient solid tumor receive chemotherapy .</brief_summary>
	<brief_title>G-CSF Preventing Neutropenia Patients With Solid Tumors Who Are Receiving Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy filgrastim ( G-CSF ) prevent persistent moderate neutropenia patient solid tumor maintain chemotherapy course . Secondary - Compare tolerability 2 regimen G-CSF patient . - Determine number course G-CSF need regimen . - Evaluate frequency infection . - Determine dose intensity . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 6 day begin 1 week start chemotherapy ( day 7-12 ) . If chemotherapy begin day 8 , patient receive G-CSF SC day 9-14 . - Arm II : Patients receive G-CSF SC every 2 day day 10-20 6 injection .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor Receiving chemotherapy line treatment ( adjuvant metastatic ) Chemotherapy course repeat every 21 day begin day 8 allow Received least 2 prior course chemotherapy Moderate neutropenia ( grade 13 ) lead delay first course â‰¥ 7 day delay second course treatment PATIENT CHARACTERISTICS : Not pregnant nursing Fertile patient must use effective contraception No known hypersensitivity filgrastim ( GCSF ) components No severe immunodepression No malignant hematological disease No history psychiatric illness No patient deprive liberty guardianship No psychological , familial , social , geographical reason prevent followup PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>neutropenia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>